Evidence map›Paper›PMID 41888103›Full record

ReviewSignal transduction and targeted therapy2026

Micronuclei: origins, assays, mechanisms, diseases and treatments.

Hailong Duan, Xin Peng, Sha Qin, Yanmin Zhou, Desheng Xiao, Yongguang Tao, Shuang Liu

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hailong DuanThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism Changsha, Changsha, Hunan, China.
Xin PengDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Sha QinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yanmin ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Desheng XiaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China. xdsh96@csu.edu.cn.ORCID http://orcid.org/0000-0003-2204-5042
Yongguang TaoThe Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism Changsha, Changsha, Hunan, China. taoyong@csu.edu.cn.ORCID http://orcid.org/0000-0003-2354-5321
Shuang LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, China. shuangliu2016@csu.edu.cn.ORCID http://orcid.org/0000-0002-7206-7277

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81874139National Natural Science Foundation of China (National Science Foundation of China) 82073097National Natural Science Foundation of China (National Science Foundation of China) 82073097 (SL)National Natural Science Foundation of China (National Science Foundation of China) 82073136National Natural Science Foundation of China (National Science Foundation of China) 82372598 (SL)National Natural Science Foundation of China (National Science Foundation of China) 8257332(SL)National Natural Science Foundation of China (National Science Foundation of China) 82573864(LC)
6 · The paper itself

Abstract

Micronuclei are small, independent cytoplasmic structures containing nuclear material. They typically form during cell division due to DNA damage or division abnormalities, serve as biomarkers of genetic damage, and are closely associated with chromosomal instability (CIN). Emerging evidence suggests that micronuclei actively promote and exacerbate CIN, with significant implications in disease pathology and potential therapeutic applications. This review provides a comprehensive overview of micronuclei by exploring their origins, formation mechanisms, and functional consequences, and detailing the fate of micronuclei post-formation, which is essential for elucidating their role in genomic instability and potential therapeutic implications. Furthermore, micronuclei can contribute to extreme chromosomal shattering and genomic instability. These processes are increasingly recognized as critical contributors to disease progression, particularly in cancer. Although micronuclei have traditionally been viewed as markers of genomic instability, recent evidence suggests that they may also serve functional roles. Their potential use as treatments for certain diseases appears theoretically feasible; however, challenges remain in selectively targeting cells to induce the formation of favorable micronuclei and maintain optimal immune responses. Addressing these questions could open new avenues for therapeutic interventions.

Indexed as

Chromosomal InstabilityDNA DamageGenomic InstabilityMicronuclei, Chromosome-DefectiveNeoplasmsAnimalsHumans

Identifiers

PMID41888103
PMCPMC13022493

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.